This could be a key move for future growth.

That is a big risk investors take when trying to find the winners and losers within the biotech sector. While we made the ...

Biogen Inc. (NASDAQ:BIIB) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, it was reported that ...

Biogen stock has delivered a strong 57.5% return over the past year, and with the current valuation checks painting a mixed ...

Biogen is running a campaign aimed at spreading awareness of the next-gen version of its spinal muscular atrophy therapy ...

June 26 (Reuters) - Biogen said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceuticals' research programs as it integrates the rare-disease drugs specialist it ...

The pharma company plans to pause or terminate investment in most of Apellis’ legacy research programmes.

When Biogen announced the deal, the company said it expected a “significant portion” of Apellis staffers would stay on board. (No-Mad/iStock/Getty Images Plus) Biogen isn’t wasting any time ...

Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but replacing lost revenues may ...

June 17 (Reuters) - Biogen has struck a deal to acquire private biotechnology company RayThera for up to $1 billion, the companies said on Wednesday, as the U.S.-listed drugmaker seeks to expand its ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q1 therapeutics ...

Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: GREY) (FRANKFURT: AGW0) (OTC: AGNPF), a Canadian healthcare ...